An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA

doi:10.1038/cgt.2013.27

CNU IR > College of Smart Living > Dept. of Senior Service and Health Management > Periodical Articles > Item 310902800/27773

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/27773

Title:	An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA
Authors:	Yen, M-C Weng, T-Y Chen, Y-L Lin, C-C Chen, C-Y Wang, C-Y Chao, H-L Chen, C-S Lai, M-D
Contributors:	老人服務事業管理系
Keywords:	H1 Promoter Ido Shrna Indoleamine 2,3-Dioxygenase Osu-Hdac42 Rna Polymerase Iii U6 Promoter
Date:	2013-06
Issue Date:	2014-05-26 10:43:05 (UTC+8)
Publisher:	Nature Publishing Group
Abstract:	Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8(+) and CD4(+) T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4(+) T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-gamma in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-alpha. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.
Relation:	Cancer Gene therapy, v.20 n.6, pp.351-357
Appears in Collections:	[Dept. of Senior Service and Health Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	2110	View/Open

Loading...